Please assess the completion status of the following clinical trial:

Trial Title: A Renal Impairment Study for PF-04965842

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Breath alcohol test at Screening and Day -1 must be negative.~* Body mass index (BMI) of ≥ 17.5 to ≤ 40.0 kg/m2; and a total body weight \>50 kg (110 lb).~Additional inclusion criteria for subjects with renal impairment:~* Meet the following eGFR criteria during the screening period based on the MDRD equation:~  * Severe renal impairment: eGFR \<30 mL/min, but not requiring hemodialysis.~ * Moderate renal impairment (Part 2 only): eGFR ≥30 mL/min and \<60 mL/min.~* Any form of renal impairment except acute nephritic syndrome (subjects with history of previous nephritic syndrome but in remission can be included).~* Stable concomitant drug regimen.~Exclusion Criteria:~* Renal transplant recipients.~* Urinary incontinence without catheterization.~* Subjects with clinically significant infections within the past 3 months (for example, those requiring hospitalization, or as judged by the Investigator), evidence of any infection (including influenza) within the past 7 days prior to baseline, history of disseminated herpes simplex infection or recurrent or disseminated herpes zoster.~* Subjects with a malignancy or with a history of malignancy, with the exception of adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ.~* History of or current positive results for human immunodeficiency virus, Hepatitis B, Hepatitis C.~Additional exclusion criteria for subjects with renal impairment:~* Subjects requiring hemodialysis and peritoneal dialysis.~* Screening BP ≥ 180 mm Hg (systolic) or ≥ 110 mm Hg (diastolic).~* Screening supine 12-lead ECG demonstrating QTcF \>470 msec or a QRS interval \>120 msec.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- PF-04965842 (Type: EXPERIMENTAL): PF 04965842 is an oral selevtive janus kinase (JAK) 1 inhibitor

Based on this trial design, predict the completion outcome and termination type (if applicable).